We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
- Authors
Tursi, A.; Elisei, W.; Picchio, M.; Penna, A.
- Abstract
The article discuses the comparison on the effectiveness of adalimumab (ADA) and infliximab (IFX) in several patients with Crohn's disease (CD). It notes that ADA and IFX have no differences as to maintaining and obtaining remission including steroid-sparing effects of the two agents. It indicates the study on patients suffering CD with anti-tumor necrosis factor-alpha therapy for a period of time in two primary care centers in southern Italy.
- Subjects
ITALY; CROHN'S disease; INFLIXIMAB; ADALIMUMAB; DISEASE remission; STEROID drugs; TUMOR necrosis factors; PRIMARY care
- Publication
Alimentary Pharmacology & Therapeutics, 2013, Vol 37, Issue 7, p763
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.12238